BioSpace News Archive

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (COVID-19) outbreak, and government-recommended and required limits on public gatherings. Holding the Annual Meeting online will also prote

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced its virtual 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will now be held at 9:00 a.m. Eastern Time. The previously announced date of the Annual Meeti

Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and Solid Tumors

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 9:00 a.m. Eastern Time. About Odonate Therapeutics, Inc. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a second amendment to the Agreement and Plan of Merger, dated March 15, 2020, asamended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, I

Arrevus Inc. ( www.arrevus.com ), a biotechnology company focused on developing novel therapeutics for orphan or serious indications, received two grants totaling $800,000 in support of its novel chaperone protein inhibitor, ARV-1502. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $300,000 grant to investigate the activity of ARV-1502 for the treatment of sepsis and the Department of D

Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no serious side effects and resulted in clinical responses in heavily pre-treated patients with metastatic breast cancer. Women with “moderately” or “well” differentiated tumors showed a higher rate of disease contr

Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, announces the launch of COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit. With results availab

ENHERTU ® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo